GC
TCRT icon

Guggenheim Capital’s Alaunos Therapeutics TCRT Stock Holding History

Guggenheim Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,102
Closed -$1.73M – 2922
2016
Q2 		$1.73M Buy
2,102
+70
+3% +$76.2K 0.01% 1658
2016
Q1 		$2.26M Sell
2,032
-1,006
-33% -$1.03M 0.01% 1480
2015
Q4 		$3.79M Sell
3,038
-380
-11% -$628K 0.01% 1171
2015
Q3 		$4.62M Sell
3,418
-15
-0.4% -$24.8K 0.01% 1078
2015
Q2 		$6.18M Buy
3,433
+2,142
+166% +$3.33M 0.02% 1055
2015
Q1 		$2.08M Buy
+1,291
New +$1.91M ﹤0.01% 1733

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Guggenheim Capital's TCRT Position: Q3 2016 in Review

Guggenheim Capital sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 2,102 shares — an estimated $1.73M sold.

Guggenheim Capital first reported a position in TCRT in Q1 2015 and held it in 6 quarters. The position peaked at $6.18M in Q2 2015. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Guggenheim Capital reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Guggenheim Capital sold 2,102 Alaunos Therapeutics shares in Q3 2016, an estimated $1.73M.
  • Guggenheim Capital first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 6 quarters.
  • Guggenheim Capital's Alaunos Therapeutics position peaked at $6.18M in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Guggenheim Capital's 13F filing for Q3 2016, filed 15 Nov 2016.